J&J buys Intra-Cellular in $14.6 billion deal, delving further into central nervous system disorders
Intra-Cellular’s pipeline of drugs under development also includes a potential treatment for anxiety and psychosis and agitation tied to Alzheimer’s disease. That drug is in mid-stage testing. J&J, ...
4d
R3 Stem Cell Publishes Landmark Peer-Reviewed Study in Frontiers in Cell and Developmental Biology
R3's Research Paper Defines Optimal Needle Parameters to Maximize Stem Cell Viability During Injection, Offering ...
Recently published Generalized Anxiety Disorder Market Insights report includes a comprehensive understanding of current ...
Efficacy and safety of durvalumab plus tremelimumab versus standard chemotherapy for non-small cell lung cancer: A systematic review and meta-analysis of phase III randomized controlled trials.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results